At this point in time, there could be a fair degree of focus on the Immunoprecise Antibodies Ltd (NASDAQ:IPA) (TSX.V:IPA) stock, which came into the news cycle earlier on in the week on Tuesday. At the time the company made a key announcement and it may be a good idea for investors to consider taking a look at it a bit more closely.
The company announced that it had signed up for a definitive share purchase agreement by way of which it is going to get control over BioStrand BV, BioKey BV and BioClue BV through its fully owned subsidiary company ImmunoPrecise Netherlands BV. The companies that the company is taking over are a number of biotech companies and pioneers in the branches of biotechnology and bioinformatics. All the entities are based out of Belgium.
It goes without saying that the latest announcement was an important one for the company and one that could have long-term ramifications with regard to its top line. The company also announced that the acquisitions are also going to help in the creation of both short-term as well as long-term opportunities for commercialization with partners and clients.
The company is looking to accomplish this through the development of an artificial intelligence-backed protein-protein interactions prediction platform. In addition to that, IPA is looking to further strengthen its own sequencing capabilities. It may be a good idea for investors to start tracking the developments a bit more closely over the course of the coming days.
Key Quote
Dr. Jennifer Bath, President and Chief Executive Officer of ImmunoPrecise Antibodies, commented, “The addition of BioStrand’s next-generation capabilities in systems omics analysis further enhances IPA’s unique ability to serve as a single-source partner to support our clients’ in silico, in vitro and in vivo research, further solidifying our position as the leading, early-stage antibody discovery contract research organization. A previously undisclosed collaboration with BioStrand has already generated unique and intriguing data and we are confident that our clients and partners will find the addition of BioStrand’s offerings both advantageous and transformational for their research programs.”
